95-659 C.M.R. ch. 248, § III - Authorized List of Uniform Childhood Vaccines

A. 2011 Base Year. For the program year commencing on July 1, 2011, the following childhood vaccines shall be available under the Program:

1. DTaP Vaccines (Diphtheria, Tetanus, acellular Pertussis)

a. Tripedia ® (Sanofi Pasteur)

b. Daptacel ® (Sanofi Pasteur)

c. Infanrix ® (GSK)

2. Hepatitis A Vaccines

a. Vaqta ® (Merck)

b. Havrix ® (GSK)

3. Hepatitis B Vaccines

a. Engerix B ® (GSK)

b. Recombivax ® (Merck)

4. Polio Vaccine

a. IPOL ® (Sanofi Pasteur)

5. Hib Vaccines (Haemophilusinfluenzae type b)

a. ActHIB ® (Sanofi Pasteur)

b. Pedvax HIB ® (Merck)

6. HPV Vaccines (Human Papillomavirus)

a. Gardasil ® (Merck)

7. Pneumococcal Vaccines

a. Prevnar 13 ® (Wyeth)

b. Pneumovax ® (Merck)

8. Meningococcal Conjugate Vaccines

a. Menactra ® (Sanofi Pasteur)

b. Menveo ® (Novartis)

9. Measles, Mumps and Rubella Vaccine

a. MMRII ® (Merck)

10. Rotavirus Vaccines

a. Rotarix ® (GSK)

b. RotaTeq ® (Merck)

11. TDAP Vaccines (Tetanus Toxoid, Reduced Diphtheria Toxoid and acellular Pertussis - adolescent formulation)

a. Boostrix ® (GSK)

b. Adacel ® (Sanofi Pasteur)

12. Varicella Vaccine

a. Varivax ® (Merck)

13. Combination Vaccines

a. Kinrix ® (GSK)

b. Pediarix ® (GSK)

c. Pentacel ® (Sanofi Pasteur)

d. ProQuad ® (Merck)

14. Influenza Vaccines

a. At least one preservative free, single dose vial presentation

b. At least one multidose vial presentation

c. At least one Influenza vaccine live Intranasal presentation

B. Uniform Vaccine Lists in Subsequent Years

1. The Board shall annually review new vaccines and vaccines not on the authorized list and determine the feasibility of either adding or removing vaccines to or from the authorized uniform list in accordance with the criteria established in section II(B).

2. In the event the Boardwhether as a result of the above annual review or for any other reason determined appropriate by the Board,determines that revision of the authorized list of uniform vaccines is warranted, it may revise the uniform vaccine list by appropriate Board vote after conducting a public hearing in accordance with 5 M.R.S.A. §8052(2), provided any revision of the list of uniform vaccines be consistent with the criteria established in 22 M.R.S.A. §1066(3)(E) and Section 2(B) of these Rules.

3. Any revision of the uniform childhood vaccine list is contingent upon the availability of adequate funding through the assessment mechanism established by 22 M.R.S.A. §1066(5).

4. The Authorized List of Uniform Childhood Vaccines shall be published on the Maine Vaccine Board Website at: http://www.mevaccine.org/mevaccine.nsf/pages/for-providers.html

5. In the event that the ACIP modifies existing product recommendations or adds a new vaccine product to the Vaccines for Children program, the Board shall meet within 90 days of the ACIP decision and determine if modifications to the authorized list of uniform vaccines is warranted.

Notes

95-659 C.M.R. ch. 248, § III